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Enterotoxigenic Escherichia coli (ETEC) is a major cause of bacterial diarrheal disease in developing countries, 
especially among children and infants. ETEC is estimated to cause 280-400 million diarrheal episodes per year 
in children <5 years of age, resulting in 300,000 to 500,000 deaths.1 Despite the need for a vaccine, there are 
currently no licensed vaccines against ETEC. Alternatively, passive immunization by oral delivery of pathogen-
specific immunoglobulins is another promising approach to provide “instant” protection against ETEC. The 
potential advantages of oral delivery are reduced cost, simplicity of administration and localized treatment within 
the GI tract. Secretory IgA (sIgA) is of particular interest because it is naturally found in the mucosal surfaces 
within the GI tract, relatively more resistant to proteolysis by digestive enzymes (vs. IgGs), and can protect 
against enteric bacteria by directly neutralizing virulence factors.2 One major challenge of this approach is the 
instability of protein molecules during oral delivery (in the digestive tract) as well as during long-term storage (in 
various formulations).  In this study, two proteins, sIgA1 and sIgA2 against heat labile toxin (LT, one of the major 
virulence factors of ETEC), were used as model sIgA molecules for developing analytical techniques and 
assessing stability (physicochemical as well as in vitro binding) under various conditions. A combination of 
biochemical and biophysical methods were employed to comprehensively characterize the sIgA1 and sIgA2 
model proteins including primary structure, post translational modifications (i.e., N-linked glycans), size, 
apparent solubility, higher order structure and conformational stability as well as in vitro antigen binding. Using 
these characterization and stability indicating methods, we are monitoring the stability of these two model sIgAs 
both in an in vitro digestion model (to mimic in vivo degradation conditions), and during accelerated stability 
studies (to assess storage stability). Our goal is to use the information gained by these aforementioned methods 
and stability studies to design stable, low-cost liquid formulations for oral delivery of sIgAs in the developing 
world.  
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Figure 1: Structure of sIgA 3 
